22 completed, 10 recruiting, 5 terminated, 5 unknown. 23 Not applicable, 8 Phase 1, 8 Phase 2, 5 Phase 3, 1 Early Phase 1.
Follow L-Citrulline: new trials by email Literature Review of L-Citrulline trials Research Report on L-Citrulline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Pre-Run Nutritional Supplements During a Fixed-Pace 5 km Treadmill Run Caffeine, L-Citrulline, Exogenous Ketone (Beta-Hydroxybutyrate) - Exercise Physiology, Nutritional Supplementation | Not applicable | Recruiting | St. Louis University | 20 | 2026-10-01 | 2026-10-02 |
| L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction L-Citrulline, Tadalafil, L-Citrulline Placebo - Erectile Dysfunction | Phase 4 | Recruiting | Beni-Suef University | 133 | 2026-06-08 | 2026-06-12 |
| L-Citrulline Versus Tamsulosin for Medical Expulsive Therapy of Distal Ureteral Stones L-Citrulline, Tamsulosin - Distal Ureteral Stone, Urolithiasis | Phase 2 | Recruiting | Beni-Suef University | 120 | 2026-05-06 | 2026-06-01 |
| L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients) L-citrulline, Placebo - Infectious Disease, Infections | Not applicable | Recruiting | Barcelona Institute for Global Health | 2200 | 2025-12-08 | 2026-02-23 |
| A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis L-citrulline, Placebo - Sickle Cell Disease | Phase 3 | Not yet recruiting | Asklepion Pharmaceuticals, LLC | 120 | 2025-07-25 | 2025-05-29 |
| Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease L-citrulline, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode | Phase 2 | Recruiting | Suvankar Majumdar | 99 | 2024-12-22 | 2026-04-13 |
| Oral Citrulline Supplementation in COPD Patients With Malnutrition L-citrulline - Chronic Obstructive Pulmonary Disease Severe, Malnutrition | Phase 3 | Unknown | University Hospital, Grenoble | 60 | 2024-01-25 | 2024-01-19 |
| L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) L-citrulline - Pregnancy, Malaria | Not applicable | Recruiting | Liverpool School of Tropical Medicine | 2960 | 2023-12-29 | 2025-06-27 |
| Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC L-Citrulline - BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension | Not applicable | Recruiting | The Hospital for Sick Children | 36 | 2023-11-01 | 2026-05-04 |
| 2 Weeks of Citrulline Supplementation on Arterial Function in Postmenopausal Women With Elevated Blood Pressure or Hypertension L-Citrulline, Placebo - Menopause, Hypertension | Not applicable | Completed | Texas Tech University | 19 | 2023-07-20 | 2025-05-15 |
| The Effect of 4 Weeks of L-Citrulline Supplementation on Macro- and Microvascular Function in Type 2 Diabetes L-citrulline, Placebo - Type 2 Diabetes | Not applicable | Completed | Texas Tech University | 36 | 2023-05-01 | 2025-05-15 |
| Effect of L-citrulline and HIIT on Arterial Stiffness, Body Composition, and Lipid Profile in Adolescents with Steatosis Associated with Metabolic Dysfunction (MASLD) L-citrulline, Carboxymethyl cellulose, High Intensity Intervals Training - Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent | Not applicable | Completed | Universidad de Guanajuato | 43 | 2023-03-14 | 2024-12-20 |
| Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation L-citrulline, Placebo - Post Deployment Related Asthma, Asthma | Phase 2 | Recruiting | University of Colorado, Denver | 75 | 2023-03-08 | 2023-04-06 |
| The Effect of Short-term L-citrulline Supplementation on Blood Pressure and Arterial Stiffness L-Citrulline, Placebo - Blood Pressure | Not applicable | Completed | European University Cyprus | 12 | 2023-01-01 | 2023-08-03 |
| A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects L-citrulline, Plasmalyte A - Ventricular Septal Defect, Atrioventricular Septal Defect | Phase 3 | Terminated | Asklepion Pharmaceuticals, LLC | 64 | 2022-06-29 | 2024-09-19 |
| Effects of L-Citrulline or Citrulline-malate on Neuromuscular Performance in Resistance-trained Adults L-citrulline, Citrulline-malate, Placebo - Neuromuscular Performance | Not applicable | Completed | Universidad de Granada | 50 | 2022-02-15 | 2022-11-04 |
| Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes L-ctirulline, Matching Placebo - Asthma, Obesity | Phase 2 | Recruiting | University of Colorado, Denver | 60 | 2021-10-01 | 2025-06-10 |
| Role of L-citrulline in Prevention of Pregnancy Associated Hypertension L-citrulline, Placebo - Pregnancy Induced Hypertension, Preeclampsia and Eclampsia | Phase 1 | Terminated | The University of Texas Medical Branch, Galveston | 3 | 2021-07-28 | 2026-09-30 |
| Novel Approaches for Improving Vascular Function in Veterans With HFpEF L-Citrulline, Placebo for L-Citrulline, BH4 - Heart Failure With Preserved Ejection Fraction, Inflammation | Phase 1 | Recruiting | VA Office of Research and Development | 90 | 2021-05-19 | 2026-04-23 |
| L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC) L-citrulline, D5 1/2NS - Acute Vaso Occlusive Crisis (VOC) | Phase 1 / Phase 2 | Terminated | Asklepion Pharmaceuticals, LLC | 30 | 2021-04-29 | 2024-09-19 |
Showing 20 of 43. Sign in to see all of them.
Hypertension (6) · Obesity (5) · Asthma (4) · Diabetes Mellitus, Type 2 (3) · Hypertension, Pulmonary (3) · Anemia, Sickle Cell (2) · Bronchopulmonary Dysplasia (2) · Premature Birth (2) · Acute Lung Injury (1) · Atrioventricular Septal Defect (1) · Communicable Diseases (1) · Eclampsia (1) · Erectile Dysfunction (1) · Fetal Growth Retardation (1) · Heart Defects, Congenital (1)
Asklepion Pharmaceuticals, LLC (6) · Texas Tech University (6) · Florida State University (3) · University of Colorado, Denver (3) · University of Pittsburgh (3) · Beni-Suef University (2) · Rennes University Hospital (2) · University Hospital, Grenoble (2) · Barcelona Institute for Global Health (1) · Baylor College of Medicine (1) · European University Cyprus (1) · Juliano Casonatto (1) · Liverpool School of Tropical Medicine (1) · Maastricht University (1) · Shahid Beheshti University of Medical Sciences (1)
United States (25) · France (3) · Egypt (2) · Germany (2) · Austria (1) · Brazil (1) · Canada (1) · Cyprus (1) · Ethiopia (1) · Iran (1) · Israel (1) · Jordan (1) · Kenya (1) · Mexico (1) · Mozambique (1)
Arturo Figueroa (4) · Fernando Holguin, MD, MPH (3) · Gurdyal Kalsi, MD, MFPM (3) · Suvankar Majumdar, MD (2) · Alan Arturo Rodriguez-Carrillo, Bachelor (1) · Arturo Figueroa, M.D. Ph.D (1) · Arturo Figueroa, Ph.D, MD (1) · Candice Fike, MD (1) · Carl A Hubel, PhD (1) · Christopher Mastropietro, MD, FCCM (1) · David W. Wray, PhD (1) · Estelle Gauda, MD (1) · Fernando Holguin, MD MPH (1) · Fredrick E. Barr, MD, MSCI (1)
PMID 25904650, PMID 31714895, PMID 36316628, PMID 37333204, PMID 37784110, PMID 37907796, PMID 39385595, PMID 39662304, PMID 39940261, PMID 42753870
2016 (1), P01HD030367 (1), R01HL073317 (1), R01HL146542 (1), R61HL167806 (1), U54NS078059 (1)